GlassScriptPhysician profile
Katherine E Huhn Usry
NPI 1700087269
$3,543.51
in general payments reported to CMS, 2019-2025
36 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $76.68 · 2021: $116 · 2022: $887 · 2023: $1,152 · 2024: $322 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.21 | 2021-2025 | |
| Lilly USA, LLC | $384.20 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $248.63 | 2019-2021 | |
| Amgen INC. | $217.62 | 2019-2023 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $209.65 | 2019-2025 | |
| Novo Nordisk INC | $186.62 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $139.90 | 2019-2025 | Airsupra, Flumist Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $139.54 | 2022-2023 | Rexulti |
| Esperion Therapeutics, INC. | $128.95 | 2022-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $102.11 | 2022-2023 | Verquvo, Belsomra, Lagevrio |
| Astellas Pharma US INC | $78.61 | 2019-2025 | Veozah |
| Axsome Therapeutics, INC. | $63.42 | 2023-2025 | Auvelity |
| Daiichi Sankyo INC. | $62.88 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.02 | 2019-2020 | |
| Pfizer INC. | $56.22 | 2019-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Huhn Usry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.